Non-Alcoholic Steatohepatitis (NASH) Market Overview, Forecast And Trends 2024-2033

The Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Non-Alcoholic Steatohepatitis (NASH) Market:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

According to The Business Research Company’s Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024, The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $3.33 billion in 2023 to $4.54 billion in 2024 at a compound annual growth rate (CAGR) of 36.3%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.

The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $14.53 billion in 2028 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.

The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in April 2021, according to the COVID-19 and Obesity: The 2021 Atlas, a report published by the World Obesity Federation, a UK-based federation that represents professional members of the scientific 2021, percentage of overweight adults recorded more than 60% of the US population, however, the obesity percentage of male expected to reach 44.2% and female 44.4% by 2025 in the US population. Therefore, the rise in the cases of obesity will drive the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

The non- alcoholic steatohepatitis (NASH) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Major companies in the non-alcoholic steatohepatitis (NASH) market are focusing on developing innovative product, such as a thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor is a protein that, upon binding with thyroid hormones, regulates gene expression and plays a crucial role in various physiological processes. For instance, in July 2023, Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company that develops and commercializes drugs, completed the submission of a New Drug Application seeking accelerated approval of Resmetirom for the treatment of NASH with liver fibrosis. This product, with key features such as once-daily oral therapy and liver-directed action, targets hepatic steatosis, inflammation, and hepatocellular injury in non-alcoholic steatohepatitis (NASH) with liver fibrosis. Its Breakthrough Therapy designation by the FDA and a comprehensive clinical development program, including Phase 3 trials, underscore its potential to address unmet medical needs, offering a promising advancement in the treatment landscape for NASH with liver fibrosis.

The non-alcoholic steatohepatitis (nash) market report table of contents includes:

Executive Summary
Non-Alcoholic Steatohepatitis (NASH) Market Characteristics
Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies
Non-Alcoholic Steatohepatitis (NASH) Market – Macro Economic Scenario
Global Non-Alcoholic Steatohepatitis (NASH) Market Size and Growth

Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking
Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Dashboard
Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market
Non-Alcoholic Steatohepatitis (NASH) Market Future Outlook and Potential Analysis
Appendix

Top 5 Major Key Players Are: